Jordi Rodon

Jordi Rodon

UNVERIFIED PROFILE

Are you Jordi Rodon?   Register this Author

Register author
Jordi Rodon

Jordi Rodon

Publications by authors named "Jordi Rodon"

Are you Jordi Rodon?   Register this Author

100Publications

3791Reads

36Profile Views

New clinical trial designs in the era of precision medicine.

Mol Oncol 2019 03 22;13(3):549-557. Epub 2019 Feb 22.

Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396357PMC
March 2019

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.

Invest New Drugs 2019 02 18;37(1):76-86. Epub 2018 Apr 18.

Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0602-0
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0602-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521838PMC
February 2019

BRAF Inhibition in BRAF-Mutant Gliomas: Results From the VE-BASKET Study.

J Clin Oncol 2018 Oct 23:JCO2018789990. Epub 2018 Oct 23.

Thomas Kaley, Lisa M. DeAngelis, Jose Baselga, and David M. Hyman, Memorial Sloan Kettering Cancer Center; Thomas Kaley, Lisa M. DeAngelis, Jose Baselga, and David M. Hyman, Weill Cornell Medical College, New York; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Mehdi Touat and Antoine Hollebecque, Institut Gustave Roussy, Villejuif; Franck Bielle, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris; Florence Joly, Centre François Baclesse, Caen; Jean-Yves Blay, Centre Léon Bérard, Lyon, France; Vivek Subbiah, MD Anderson Cancer Center, Houston, TX; Jordi Rodon, Vall d'Hebron University Hospital, Barcelona, Spain; A. Craig Lockhart, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Vicki Keedy, Vanderbilt University Medical Center, Nashville, TN; Ralf-Dieter Hofheinz, Universitätsmedizin Mannheim, Mannheim; Jurgen Wolf, Universitätsklinikum Köln, Cologne, Germany; Ian Chau, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Noopur S. Raje, Massachusetts General Hospital, Boston, MA; Martina Makrutzki, F Hoffmann-La Roche, Basel, Switzerland; Todd Riehl, Genentech, South San Francisco, CA; and Bethany Pitcher, F Hoffmann-La Roche, Mississauga, Ontario, Canada.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9990
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9990DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286161PMC
October 2018

Precision oncology: East meets West.

Int J Cancer 2018 05 4;142(9):1734-1737. Epub 2018 Jan 4.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31218DOI Listing
May 2018

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

J Clin Oncol 2018 05 5;36(13):1291-1299. Epub 2018 Feb 5.

Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research Institute and Tennessee Oncology; Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands; Mark R. Middleton, National Institute for Health Research, Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; Martin Schuler, West German Cancer Center, University Duisburg-Essen, and German Cancer Consortium, Partner Site University Hospital Essen, Essen; Ruth Seggewiss-Bernhardt, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Douglas Bootle, David Demanse, Lars Blumenstein, and Cornelia Quadt, Novartis Pharma AG, Basel, Switzerland; Christina Coughlin, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.7107
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.7107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920739PMC
May 2018

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.

Genome Med 2018 03 28;10(1):25. Epub 2018 Mar 28.

Research Program on Biomedical Informatics (GRIB), IMIM Hospital del Mar Medical, Research Institute and Pompeu Fabra University, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-018-0531-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875005PMC
March 2018

Development of Molecularly Driven Targeted Combination Strategies.

Oncologist 2017 12 16;22(12):1421-1423. Epub 2017 Oct 16.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) and Khalifa Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2017-0402DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728037PMC
December 2017

First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours.

Eur J Cancer 2017 08;81:142-150

Drug Development Department DITEP, Institut Gustave Roussy, 94805, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Orsay, 91405, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.007DOI Listing
August 2017

Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness.

Cancer Discov 2017 07;7(7):666-669

Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-17-0500DOI Listing
July 2017

Immuno-Oncology: The Third Paradigm in Early Drug Development.

Target Oncol 2017 04;12(2):125-138

Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-016-0471-4DOI Listing
April 2017

The expanding role of immunotherapy.

Cancer Treat Rev 2017 Mar 11;54:74-86. Epub 2017 Feb 11.

Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Pg. Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.01.008DOI Listing
March 2017

Unveiling changes in the landscape of patient populations in cancer early drug development.

Oncotarget 2017 Feb;8(8):14158-14172

Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.13258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355170PMC
February 2017

Epileptic features and survival in glioblastomas presenting with seizures.

Epilepsy Res 2017 02 26;130:1-6. Epub 2016 Dec 26.

Neuropathology Unit, Pathology Department, Vall d́Hebron University Hospital, Hospital Vall d'Hebron, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eplepsyres.2016.12.013DOI Listing
February 2017

Principles of pharmacotherapy.

Handb Clin Neurol 2016 ;134:149-62

Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-802997-8.00009-8DOI Listing
December 2016

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.

Clin Cancer Res 2016 Oct 13;22(20):5049-5057. Epub 2016 May 13.

Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2474DOI Listing
October 2016

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.

Neuro Oncol 2016 08 21;18(8):1146-56. Epub 2016 Feb 21.

Medical Oncology Department, Bellaria-Maggiore Hospitals, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy (A.A.B.); Hôpital Avicenne, Paris 13 University, Bobigny, France (A.F.C.); University of California San Diego Health System, La Jolla, California (S.K.); Hospital Universitario 12 de Octubre, Madrid, Spain (J.M.S.-S.); Department of Oncology, Royal North Shore Hospital, St Leonards, Australia (H.R.W.); CHU Hôspital De La Timone, Rue Saint Pierre, France (O.C.); Austin Hospital, Heidelberg, Australia (L.C.); Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Frankfurt, Germany (J.P.S.); Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany (D.C.); Antwerp University Hospital, Edegem, Belgium (P.S.); Medical Oncology, Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain (J.R.); Eli Lilly and Company, Erl Wood, England (A.C., C.S., I.G., C.M.); Eli Lilly and Company, Indianapolis, Indiana (S.C.G., D.D., M.M.L.); Neurology Clinic, University of Heidelberg, Heidelberg, Germany (W.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933481PMC
August 2016

Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies.

Am Soc Clin Oncol Educ Book 2012 :168-72

From the Molecular Therapeutics Research Unit, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.168DOI Listing
April 2016

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.

Mol Cancer Ther 2016 04 23;15(4):533-47. Epub 2016 Mar 23.

Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0643DOI Listing
April 2016

Prognostic implications of epilepsy in glioblastomas.

Clin Neurol Neurosurg 2015 Dec 22;139:166-71. Epub 2015 Oct 22.

Neuropathology Unit, Pathology Department, Vall d́Hebron University Hospital, Hospital Vall d'Hebron, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2015.10.002DOI Listing
December 2015

The Personalization of Therapy: Molecular Profiling Technologies and Their Application.

Semin Oncol 2015 Dec 30;42(6):775-87. Epub 2015 Sep 30.

Vall d'Hebron University Hospital and Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00937754150019
Publisher Site
http://dx.doi.org/10.1053/j.seminoncol.2015.09.026DOI Listing
December 2015

Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.

Semin Oncol 2015 Dec 24;42(6):801-19. Epub 2015 Sep 24.

Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.09.027DOI Listing
December 2015

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

J Clin Oncol 2015 Oct 31;33(30):3401-8. Epub 2015 Aug 31.

Josep Tabernero, Rodrigo Dienstmann, Barbara Adamo, and Jordi Rodon, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal; Victor Moreno, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain; Rastislav Bahleda, Anas Gazzah, and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif; Antoine Italiano, Institut Bergonié, Bordeaux, France; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Alain Mita, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Bob Zhong, Suso J. Platero, Moitreyee Chatterjee-Kishore, Vijay Peddareddigari, and Feng R. Luo, Janssen Research and Development, Raritan, NJ; and Johan W. Smit and Kim Stuyckens, Janssen Research and Development, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.7341DOI Listing
October 2015

Other targeted drugs in melanoma.

Ann Transl Med 2015 Oct;3(18):266

1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2015.08.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630555PMC
October 2015

Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.

Mol Oncol 2015 May 15;9(5):940-50. Epub 2014 Jul 15.

Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.06.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528747PMC
May 2015

Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

Nat Rev Clin Oncol 2015 Apr 25;12(4):197-212. Epub 2014 Nov 25.

Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2014.202
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2014.202DOI Listing
April 2015

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Sci Transl Med 2015 Apr;7(283):283ra51

Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaa4442DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433148PMC
April 2015

Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies.

Discov Med 2015 Feb;19(103):101-8

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
February 2015

Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.

Discov Med 2015 Feb;19(103):109-16

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
February 2015

A framework for genomic biomarker actionability and its use in clinical decision making.

Oncoscience 2014 22;1(10):614-623. Epub 2014 Oct 22.

Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego, California, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278279PMC
January 2015

Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.

Discov Med 2014 Dec;18(101):323-30

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
December 2014

Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection.

Oncologist 2013 17;18(11):1180-8. Epub 2013 Oct 17.

Molecular Therapies Research Unit, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825301PMC
October 2014

An (only) partially established paradigm of drug development of targeted therapies.

Authors:
Jordi Rodon

Eur J Cancer 2014 Aug 4;50(12):2037-9. Epub 2014 Jun 4.

Medical Oncology Department, Vall d'Hebrón University Hospital, Barcelona, Spain; Vall d'Hebrón Institute of Oncology, Barcelona, Spain; Universitat Autonoma de Barcelona, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.04.029DOI Listing
August 2014

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.

Mol Cancer Ther 2014 May 18;13(5):1021-31. Epub 2014 Apr 18.

Authors' Affiliations: Molecular Therapeutics Research Unit, Medical Oncology Department; and Experimental Therapeutics Group, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0639DOI Listing
May 2014

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 12;20(7):1900-9. Epub 2014 Feb 12.

Authors' Affiliations: Vall d'Hebron Institut d'Oncologia and Universitat Autonoma of Barcelona, Barcelona, Spain; University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; University of Leicester, Leicester, United Kingdom; University Hospital of Zürich, Zürich, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, New York; Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1710DOI Listing
April 2014

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.

Clin Cancer Res 2014 Jan 28;20(1):233-45. Epub 2013 Oct 28.

Authors' Affiliations: Dana-Farber Cancer Institute; Massachusetts General Hospital; Beth Israel Deaconess Medical Center, Boston, Massachusetts; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Mary Crowley Cancer Research Centers, Dallas, Texas; Exelixis Inc., South San Francisco, California; and Sanofi, Cambridge, Massachusetts, and Vitry-sur-Seine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1777DOI Listing
January 2014

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.

Sci Rep 2013 Dec 18;3:3544. Epub 2013 Dec 18.

1] Breast Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain [2] Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep03544DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506566PMC
December 2013

Biomarker-driven patient selection for early clinical trials.

Curr Opin Oncol 2013 May;25(3):305-12

Molecular Therapeutics Research Unit, Medical Oncology Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32835ff3cbDOI Listing
May 2013

Genomic medicine frontier in human solid tumors: prospects and challenges.

J Clin Oncol 2013 May 15;31(15):1874-84. Epub 2013 Apr 15.

Vall d'Hebron University Hospital, P. Vall d'Hebron 119-122, Barcelona, Spain 08035.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.2268DOI Listing
May 2013

Development of PI3K inhibitors: lessons learned from early clinical trials.

Nat Rev Clin Oncol 2013 Mar 12;10(3):143-53. Epub 2013 Feb 12.

Medical Oncology Department, Vall d'Hebrón University Hospital, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119, Edifici Maternoinfantil Planta 14, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2013.10
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2013.10DOI Listing
March 2013

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Mol Cancer Ther 2012 Sep 21;11(9):2062-71. Epub 2012 Jun 21.

Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/content/11/9/2062.full.pdf
Web Search
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-12
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-12-0290DOI Listing
September 2012

Emerging therapies for urothelial cancer.

Cancer Treat Rev 2012 Jun 22;38(4):311-7. Epub 2011 Nov 22.

Genitourinary, Sarcoma and Central Nervous System Tumors Program, Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autonoma Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2011.10.007DOI Listing
June 2012

Molecular prescreening to select patient population in early clinical trials.

Nat Rev Clin Oncol 2012 04 3;9(6):359-66. Epub 2012 Apr 3.

Medical Oncology Department, Vall d'Hebrón University Hospital, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.48DOI Listing
April 2012

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).

Cancer Chemother Pharmacol 2012 Mar 6;69(3):825-34. Epub 2011 Nov 6.

Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1770-1DOI Listing
March 2012

R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.

PLoS One 2011 11;6(10):e26060. Epub 2011 Oct 11.

Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026060PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191161PMC
February 2012

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.

Cancer Chemother Pharmacol 2012 Feb 6;69(2):563-71. Epub 2011 Nov 6.

Division of Oncology, Department of Medicine, Stanford University and Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1772-zDOI Listing
February 2012

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.

Recent Pat Anticancer Drug Discov 2011 May;6(2):210-36

Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, 08035, Spain.

View Article

Download full-text PDF

Source
May 2011

Combining targeted therapies: practical issues to consider at the bench and bedside.

Oncologist 2010 15;15(1):37-50. Epub 2010 Jan 15.

Servei d'Oncologia Medica, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institute of Oncology (V.H.I.O), Passatge Vall d'Hebron 119, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2009-0117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227881PMC
May 2010

Molecular basis for the treatment of renal cell carcinoma.

Clin Transl Oncol 2010 Jan;12(1):15-21

Department of Medical Oncology, Vall d'Hebrón University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s12094-010-0461
Web Search
http://link.springer.com/10.1007/s12094-010-0461-4
Publisher Site
http://dx.doi.org/10.1007/s12094-010-0461-4DOI Listing
January 2010

Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.

Eur J Cancer 2009 Sep;45 Suppl 1:309-17

Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0959-8049(09)70045-0DOI Listing
September 2009

Development of PARP inhibitors in oncology.

Expert Opin Investig Drugs 2009 Jan;18(1):31-43

UT MD Anderson Cancer Center, Investigational Cancer Therapeutics, (Unit 455), 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543780802525324DOI Listing
January 2009